Haydar attended the VISIONS conference in 2024, and shares that the experience was incredible for him and his family, especially as they navigate his daughter’s diagnosis with LCA. Now, he’s inviting others to join him at United in Vision 2026! For a limited time, save 10% on

Mike Hess, Founder of the Blind Institute of Technology, knows the power of bringing communities together to drive innovation and opportunity. That’s why he’s rallying our community around United in Vision 2026. United in Vision 2026 brings together the Foundation Fighting

Regenerative medicine is changing how scientists think about treating inherited retinal diseases (IRDs) and AMD. In this episode of Glimpse with Glaze, Dr. Yannis Paulus, retina specialist and clinician scientist at the Wilmer Eye Institute at Johns Hopkins University, explains

🎙️ We’re celebrating 100 episodes of the Eye on the Cure Podcast! To mark this milestone, host Ben Shaberman revisits some of the most powerful conversations that have shaped the podcast and highlighted the momentum advancing treatments and cures for blinding diseases. This

The Foundation Fighting Blindness community mourns the loss of Karen Petrou, our Board Chair, who passed away after a private battle with liver cancer. Throughout her many years of service to the Foundation, Karen was an extraordinary force for progress, advocacy, and hope for

Partner News: Individuals living with Stargardt disease and caregivers are invited to complete a brief survey (25–30 minutes). Insights gathered may help shape research efforts and inform the development of treatments and cures — ensuring that the perspectives of the Stargardt

For AMD & Low Vision Awareness Month, we’re sharing a new episode of Glimpse with Glaze—created for eye care professionals. In this episode, Dr. Erin Kenny, Chief of the William Feinbloom Vision Rehabilitation Center at the Pennsylvania College of Optometry, explains what a low

A new development in the advancement of potential treatments for thyroid eye disease (TED): The FDA has accepted a BLA from our corporate partner, Viridian Therapeutics (@viridianthera), for veligrotug, an investigational therapy for people living with TED. The application has

Age-related macular degeneration (AMD) is a progressive disease, but how it progresses and how it affects daily life vary from person to person. Some experience gradual changes in central vision, like blurring or wavy lines. Others may notice more significant shifts over time.

International Day of Women and Girls in Science is February 11, and we’re marking the moment by spotlighting Dr. Jillian Pearring—a scientist funded by the Foundation Fighting Blindness. As head of her own lab at the University of Michigan, Dr. Pearring is leading discovery

🎧 Our CEO Jason Menzo recently joined the Blind & Beyond radio show to discuss the momentum behind vision research—and what it means for advancing treatments and cures for blinding diseases. From advocacy efforts on Capitol Hill to what’s ahead at United in Vision 2026 (June

In our latest episode of the Eye on the Cure podcast, Dr. Prem Subramanian of the University of Colorado Sue Anschutz-Rodgers Eye Center and School of Medicine joins host Ben Shaberman to discuss thyroid eye disease (TED)—a condition that is often misdiagnosed and can lead to

What do you really know about AMD? February is AMD & Low Vision Awareness Month, so we’re sharing important information about age-related macular degeneration (AMD). AMD affects millions and can progress differently for each person. This video explains the basics — from dry vs.

Introducing Glimpse with Glaze: a new series for eye care professionals exploring inherited retinal diseases (IRDs) and age-related macular degeneration (AMD). In our latest episode, Ben Shaberman, former VP of Science Communications, joins Michelle Glaze to discuss why

A full-circle moment worth celebrating 💙 We’re excited to welcome Two Blind Brothers (@TwoBlindBros) as the presenting sponsor of the 2026 New York Night for Sight gala—10 years after they launched their organization at this very event. Taking place on May 14, 2026, in New

A new clinical trial is now enrolling for individuals with ABCA4-related Stargardt disease. The CELESTE Study, sponsored by AAVantgarde Bio, is a first-in-human Phase 1/2 clinical trial evaluating an investigational gene therapy designed to address the genetic cause of Stargardt

February is AMD & Low Vision Awareness Month! This month, we’re raising awareness about age-related macular degeneration and low vision — while spotlighting accessible technology, low vision aids, and everyday strategies shared by our community and partners. We’ll also be

Curious about the latest in AMD research and care? 🧬 Whether you’re living with AMD, supporting a loved one, or a healthcare professional, our Quarterly Vision Webinar on February 28 at 12 p.m. ET has something for you! Learn from top experts about breakthroughs, treatments on

Congratulations to RD Fund portfolio company @AtsenaThera on their manufacturing partnership with Genezen! This collaboration supports the pivotal LIGHTHOUSE study for XLRS gene therapy ATSN-201, on track for potential BLA filing in 2028. Learn more at

Start the year with intention. A donor-advised fund is one way to plan your giving while supporting research advancing treatments and cures for blinding diseases. Learn more as you plan for 2026. https://t.co/KZXqEiNhTJ